Jones Financial Companies Lllp Buys 5,656 Shares of Becton, Dickinson and Company $BDX

Jones Financial Companies Lllp lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 8.2% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 74,332 shares of the medical instruments supplier’s stock after acquiring an additional 5,656 shares during the period. Jones Financial Companies Lllp’s holdings in Becton, Dickinson and Company were worth $13,743,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Brighton Jones LLC grew its stake in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares during the period. Empowered Funds LLC increased its holdings in shares of Becton, Dickinson and Company by 20.4% during the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after acquiring an additional 1,354 shares in the last quarter. Ameritas Advisory Services LLC acquired a new position in shares of Becton, Dickinson and Company during the second quarter worth approximately $40,000. Grimes & Company Inc. lifted its holdings in shares of Becton, Dickinson and Company by 10.8% in the 2nd quarter. Grimes & Company Inc. now owns 1,472 shares of the medical instruments supplier’s stock worth $254,000 after purchasing an additional 144 shares in the last quarter. Finally, Valeo Financial Advisors LLC grew its position in Becton, Dickinson and Company by 27.4% in the 2nd quarter. Valeo Financial Advisors LLC now owns 1,645 shares of the medical instruments supplier’s stock valued at $283,000 after purchasing an additional 354 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the sale, the director owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 2,680 shares of company stock valued at $539,848 in the last 90 days. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $207.82 on Thursday. The firm has a market cap of $59.21 billion, a PE ratio of 35.65, a P/E/G ratio of 2.28 and a beta of 0.25. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69. The business has a 50 day moving average of $199.25 and a 200-day moving average of $191.87. Becton, Dickinson and Company has a 12-month low of $162.29 and a 12-month high of $245.23.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. The business had revenue of $5.89 billion for the quarter, compared to analyst estimates of $5.91 billion. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.Becton, Dickinson and Company’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period last year, the company posted $3.81 earnings per share. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company declared that its Board of Directors has authorized a share repurchase program on Tuesday, January 27th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a dividend of $1.05 per share. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 annualized dividend and a yield of 2.0%. Becton, Dickinson and Company’s dividend payout ratio is presently 72.04%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Citigroup initiated coverage on shares of Becton, Dickinson and Company in a report on Tuesday. They set a “buy” rating and a $233.00 price objective on the stock. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Piper Sandler boosted their price objective on Becton, Dickinson and Company from $190.00 to $205.00 and gave the stock a “neutral” rating in a report on Wednesday, January 28th. Morgan Stanley raised their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Finally, Bank of America lifted their target price on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research report on Monday, January 5th. Five investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus target price of $213.36.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.